ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
French biotech firm Deinove is changing focus from biofuels to carotenoids and antibiotics for human health. The company was founded on research into rare bacteria including Deinococcus strains, which it says can degrade complex organic material into smaller compounds. But the firm’s biofuel ambitions were sidelined by low oil prices and lack of government support. Now, Deinove plans to work on a “high potential” antibiotic lead. In addition, it will develop carotenoid strains and nutrition and cosmetic products with firms including Flint Hills Resources.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X